Melanocortin Peptides: PT-141, Melanotan II, and the MC Receptor System

The Melanocortin System

The melanocortin system is one of the most versatile signaling networks in human physiology. It consists of five G-protein-coupled receptors (MC1R through MC5R), their endogenous peptide ligands (derived from proopiomelanocortin, or POMC), and endogenous antagonists (agouti-related peptide, AGRP, and agouti signaling protein, ASIP).

This system regulates an remarkably diverse range of biological processes:

Receptor	Primary Location	Key Functions
MC1R	Melanocytes, immune cells	Pigmentation, anti-inflammatory signaling
MC2R	Adrenal cortex	Cortisol synthesis (ACTH receptor)
MC3R	Hypothalamus, gut	Energy homeostasis, nutrient partitioning
MC4R	Hypothalamus, CNS	Appetite regulation, sexual function, energy expenditure
MC5R	Exocrine glands, adipose	Sebaceous gland function, lipolysis

Endogenous Melanocortin Ligands

All melanocortin receptor ligands derive from a single precursor protein — proopiomelanocortin (POMC) — which is cleaved into multiple bioactive peptides:

• alpha-MSH (α-melanocyte-stimulating hormone): The primary melanocortin agonist. Binds MC1R (pigmentation), MC3R, MC4R (appetite/sexual function), MC5R
• beta-MSH and gamma-MSH: Related MSH peptides with overlapping receptor profiles
• ACTH (adrenocorticotropic hormone): Binds MC2R (cortisol production) and other MCRs
• beta-endorphin: An opioid peptide co-produced from POMC (distinct from the melanocortin pathway)

The core pharmacophore (receptor-binding sequence) shared by all melanocortins is the tetrapeptide His-Phe-Arg-Trp — this four-amino-acid motif is essential for melanocortin receptor activation.

Melanotan II: The Non-Selective Melanocortin Agonist

Development History

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-MSH developed at the University of Arizona in the 1980s by Victor Hruby and Mac Hadley. The original research goal was to develop a sunless tanning agent that would reduce skin cancer risk by stimulating melanogenesis (melanin production) without UV exposure.

The structure of MT-II (Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2) incorporates several modifications to the native alpha-MSH sequence:

• Cyclization: A lactam bridge between Asp and Lys constrains the peptide in its bioactive conformation, dramatically increasing receptor affinity and metabolic stability
• D-Phenylalanine: Substitution of L-Phe with D-Phe enhances receptor binding and proteolytic resistance
• Norleucine: Replaces methionine to prevent oxidation
• N-terminal acetylation and C-terminal amidation: Block exopeptidase degradation

Receptor Profile

MT-II is a potent but non-selective melanocortin agonist — it activates MC1R, MC3R, MC4R, and MC5R with high affinity. This broad receptor profile explains its diverse biological effects:

• MC1R activation → Melanogenesis: Stimulates melanocytes to produce eumelanin (the brown-black pigment that provides UV protection)
• MC4R activation → Sexual function: MC4R activation in the hypothalamus and spinal cord mediates sexual arousal through autonomic nervous system pathways
• MC3R/MC4R activation → Appetite suppression: Central melanocortin signaling reduces food intake and increases energy expenditure
• MC1R activation → Anti-inflammatory: MC1R signaling on immune cells reduces NF-kB-mediated inflammation

PT-141 (Bremelanotide): The Selective MC4R-Targeted Peptide

Development

PT-141 (Bremelanotide, Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH) is a metabolite of Melanotan II that was specifically developed for sexual dysfunction research. It differs from MT-II by a single modification: the C-terminal amide (-NH2) is replaced with a free carboxyl (-OH).

This seemingly minor change produces a significant pharmacological shift — PT-141 retains strong MC4R and MC3R agonism (the receptors mediating sexual function) while having reduced MC1R activity (the pigmentation receptor). This makes PT-141 more targeted for sexual function research with reduced melanogenic side effects.

FDA Approval

PT-141 (marketed as Vyleesi) was approved by the FDA in June 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. This was a landmark approval:

• First FDA-approved treatment for female sexual desire disorder that acts through a central (CNS) mechanism
• First melanocortin-based drug approved for any indication
• Demonstrated that peptide-based CNS-active therapeutics could navigate the full regulatory pathway

Mechanism of Action

PT-141’s effects on sexual function are mediated centrally (in the brain) rather than peripherally (in the vasculature):

1. MC4R activation in the hypothalamus: PT-141 activates MC4R neurons in the medial preoptic area and paraventricular nucleus — brain regions that integrate sexual motivation and arousal signals
2. Descending autonomic pathways: Hypothalamic MC4R signaling activates descending pathways to the spinal cord that control genital autonomic responses
3. Dopaminergic facilitation: MC4R activation in the hypothalamus facilitates dopamine release in the mesolimbic pathway, contributing to the motivational (desire) component

This CNS mechanism fundamentally distinguishes PT-141 from PDE5 inhibitors (sildenafil, tadalafil), which work peripherally on vascular smooth muscle. PT-141 addresses desire and arousal at the level of brain signaling, while PDE5 inhibitors address the vascular mechanics of erectile function.

The MC4R Receptor: A Hub for Metabolism and Behavior

MC4R deserves special attention because it sits at the intersection of multiple research-relevant pathways:

Appetite and Energy Balance

MC4R in the arcuate nucleus of the hypothalamus is the primary integrator of energy balance signals:

• POMC/alpha-MSH neurons activate MC4R → satiety signal (stop eating)
• AgRP neurons release agouti-related peptide, which antagonizes MC4R → hunger signal (start eating)
• MC4R loss-of-function mutations are the most common monogenic cause of obesity in humans, affecting 2-6% of severely obese individuals

Sexual Function

MC4R in the medial preoptic area and paraventricular nucleus mediates the central component of sexual arousal in both males and females — the pathway targeted by PT-141.

Cardiovascular Effects

MC4R activation can transiently increase heart rate and blood pressure. This is a known effect of both MT-II and PT-141 and is monitored in clinical studies. The cardiovascular effects are generally mild and self-limiting but represent a pharmacological consideration.

Comparing MT-II and PT-141

Feature	Melanotan II	PT-141 (Bremelanotide)
Structure	Cyclic heptapeptide, C-terminal amide	Cyclic heptapeptide, C-terminal carboxyl
MC1R (pigmentation)	High affinity	Reduced affinity
MC4R (sexual function)	High affinity	High affinity
Pigmentation effect	Significant	Minimal
Sexual function effect	Yes	Yes (primary indication)
FDA status	Not approved	Approved (Vyleesi, 2019)
Route	Subcutaneous	Subcutaneous (approved), intranasal (studied)

The Pigmentation Pathway: MC1R Signaling

Understanding MC1R signaling is essential context for melanocortin peptide research:

1. MC1R activation: Alpha-MSH or MT-II binds MC1R on melanocytes
2. cAMP cascade: MC1R couples to Gs protein → adenylyl cyclase → increased intracellular cAMP
3. MITF activation: cAMP activates protein kinase A (PKA), which phosphorylates CREB, which transcribes MITF (microphthalmia-associated transcription factor)
4. Melanogenic enzyme expression: MITF activates transcription of tyrosinase, TRP-1, and TRP-2 — the enzymes that synthesize melanin
5. Eumelanin production: The resulting melanin is primarily eumelanin (brown-black pigment), which provides more effective UV protection than pheomelanin (red-yellow pigment)

The switch from pheomelanin to eumelanin synthesis is significant — individuals with red hair and fair skin (who carry MC1R variants that favor pheomelanin) have higher skin cancer risk. Research into MC1R agonists explores whether pharmacological eumelanin induction could provide photoprotection.

Safety Considerations in Research

Melanocortin peptides have several pharmacological effects that are important for research design:

• Cardiovascular: MC4R activation can produce transient increases in blood rate and blood pressure
• Nausea: A common dose-dependent side effect of MC4R agonists, likely mediated by central melanocortin signaling in the area postrema
• Pigmentation changes: MC1R agonism (primarily MT-II) can produce diffuse skin darkening, darkening of existing nevi (moles), and new nevi formation
• Appetite suppression: MC3R/MC4R-mediated anorexia — this is a pharmacological effect, not a side effect, but may confound research designs not targeting appetite

Frequently Asked Questions

What is the relationship between Melanotan II and PT-141?

PT-141 is a metabolite of Melanotan II — when MT-II is administered, one of its metabolic products is PT-141. Researchers at Palatin Technologies isolated this metabolite and developed it independently because it retained the sexual function effects (MC4R agonism) while having reduced pigmentation effects (lower MC1R activity).

How does PT-141 differ from Viagra (sildenafil)?

PT-141 works centrally in the brain through MC4R activation, affecting sexual desire and arousal at the level of hypothalamic signaling. Sildenafil works peripherally by inhibiting PDE5 in vascular smooth muscle, increasing blood flow to genital tissue. They target completely different aspects of sexual function — desire/arousal (PT-141) versus vascular mechanics (sildenafil) — and work through unrelated mechanisms.

Can melanocortin peptides cause permanent skin darkening?

In research contexts, melanocortin-induced pigmentation (primarily from MT-II) typically fades over weeks to months after discontinuation as melanin-containing keratinocytes undergo natural turnover. However, the timeline depends on the duration and dose of exposure, and some pigmentation changes may be persistent. New nevi (moles) induced during exposure may be permanent.

Why are melanocortin peptides relevant to obesity research?

MC4R is the single most important known genetic locus for human obesity. MC4R loss-of-function mutations cause severe early-onset obesity. Conversely, MC4R agonists reduce food intake and increase energy expenditure. This makes the melanocortin system a major pharmaceutical target for anti-obesity drug development — setmelanotide (Imcivree), an MC4R agonist, is FDA-approved for genetic obesity conditions.

Are melanocortin peptides related to alpha-MSH-derived anti-inflammatory peptides like KPV?

Yes. KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-MSH, which is itself a melanocortin peptide derived from POMC. While full-length alpha-MSH activates all melanocortin receptors, the KPV fragment has potent anti-inflammatory activity (NF-kB inhibition) without significant melanocortin receptor activation — it represents a different functional domain of the same parent molecule.

References

1. Hadley ME, Dorr RT. “Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.” Peptides. 2006;27(4):921-930.
2. Kingsberg SA, et al. “Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials.” Obstet Gynecol. 2019;134(5):899-908.
3. Wikberg JE, Mutulis F. “Targeting melanocortin receptors: an approach to treat weight disorders and sexual dysfunction.” Nat Rev Drug Discov. 2008;7(4):307-323.
4. Hruby VJ, et al. “Cyclic lactam alpha-melanotropin analogues of Ac-Nle4-cyclo[Asp5, D-Phe7, Lys10] alpha-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors.” J Med Chem. 1995;38(18):3454-3461.
5. Clément K, et al. “MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency.” Nat Med. 2018;24(5):551-555.
6. Dorr RT, et al. “Effects of superpotent melanotropic peptides on the melanocortin receptors.” Life Sci. 1996;58(16):1341-1347.
7. Molinoff PB, et al. “PT-141: a melanocortin agonist for the treatment of sexual dysfunction.” Ann N Y Acad Sci. 2003;994:96-102.
8. Cai M, Hruby VJ. “The melanocortin receptor system: a target for multiple degenerative diseases.” Curr Protein Pept Sci. 2016;17(5):488-496.